Jan Jobsen

7PUBLICATIONS
39CO-AUTHORS
Predictive and prognostic markersCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 07, 2024
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.

Dione van Dijk, Lisa Vermij, Alicia León-Castillo

|Sep 29, 2023
Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.

Amy Jamieson, Lisa Vermij, Claire J H Kramer

|Jul 24, 2023
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.

Nanda Horeweg, Remi A Nout, Ina M Jürgenliemk-Schulz

|May 25, 2023
QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction.

Anne Sophie V M Van den Heerik, Natalja T Ter Haar, Lisa Vermij

|Jan 23, 2023
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.

Lisa Vermij, Jan J Jobsen, Alicia León-Castillo

|Aug 08, 2022
The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.

Jan J Jobsen, Henk Struikmans, Ester Siemerink

Pageof 2

Frequent Collaborators

5 joint publications

Carien L Creutzberg

5 joint publications

Tjalling Bosse

4 joint publications

Lisa Vermij

4 joint publications

Nanda Horeweg